2.25
+0.61(+37.20%)
Currency In USD
| Previous Close | 1.64 |
| Open | 2.1 |
| Day High | 2.82 |
| Day Low | 1.83 |
| 52-Week High | 2.82 |
| 52-Week Low | 0.39 |
| Volume | 168.48M |
| Average Volume | 10.94M |
| Market Cap | 164.23M |
| PE | -1.83 |
| EPS | -1.23 |
| Moving Average 50 Days | 0.57 |
| Moving Average 200 Days | 0.91 |
| Change | 0.61 |
If you invested $1000 in Rani Therapeutics Holdings, Inc. (RANI) since IPO date, it would be worth $204.55 as of October 21, 2025 at a share price of $2.25. Whereas If you bought $1000 worth of Rani Therapeutics Holdings, Inc. (RANI) shares 3 years ago, it would be worth $317.8 as of October 21, 2025 at a share price of $2.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
GlobeNewswire Inc.
Oct 17, 2025 11:31 AM GMT
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir ImranAt the closing of the financing, each of Samsara and Anomal
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
GlobeNewswire Inc.
Oct 17, 2025 11:30 AM GMT
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit royalties on product sales for the first license agr
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
GlobeNewswire Inc.
Jul 15, 2025 1:00 PM GMT
SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that